Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

T Taniguchi; M Tischkowitz; N Ameziane; S V Hodgson; C G Mathew; H Joenje; S C Mok; A D D'Andrea

doi:10.1038/nm852

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

T Taniguchi, M Tischkowitz, N Ameziane, S V Hodgson, C G Mathew, H Joenje, S C Mok, A D D'Andrea

Research output: Contribution to journal › Article › peer-review

491 Citations (Scopus)

Abstract

Ovarian tumor cells are often genomically unstable and hypersensitive to cisplatin. To understand the molecular basis for this phenotype, we examined the integrity of the Fanconi anemia-BRCA (FANC-BRCA) pathway in those cells. This pathway regulates cisplatin sensitivity and is governed by the coordinate activity of six genes associated with Fanconi anemia (FANCA, FANCC, FANCD2, FANCE, FANCF and FANCG) as well as BRCA1 and BRCA2 (FANCD1). Here we show that the FANC-BRCA pathway is disrupted in a subset of ovarian tumor lines. Mono-ubiquitination of FANCD2, a measure of the function of this pathway, and cisplatin resistance were restored by functional complementation with FANCF, a gene that is upstream in this pathway. FANCF inactivation in ovarian tumors resulted from methylation of its CpG island, and acquired cisplatin resistance correlated with demethylation of FANCF. We propose a model for ovarian tumor progression in which the initial methylation of FANCF is followed by FANCF demethylation and ultimately results in cisplatin resistance.

Original language	English
Pages (from-to)	568 - 574
Number of pages	7
Journal	Nature Medicine
Volume	9
Issue number	5
DOIs	https://doi.org/10.1038/nm852
Publication status	Published - 1 May 2003

Access to Document

10.1038/nm852

Cite this

@article{3b7e5834a1244e0b8203ed600a8c9aae,

title = "Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors",

abstract = "Ovarian tumor cells are often genomically unstable and hypersensitive to cisplatin. To understand the molecular basis for this phenotype, we examined the integrity of the Fanconi anemia-BRCA (FANC-BRCA) pathway in those cells. This pathway regulates cisplatin sensitivity and is governed by the coordinate activity of six genes associated with Fanconi anemia (FANCA, FANCC, FANCD2, FANCE, FANCF and FANCG) as well as BRCA1 and BRCA2 (FANCD1). Here we show that the FANC-BRCA pathway is disrupted in a subset of ovarian tumor lines. Mono-ubiquitination of FANCD2, a measure of the function of this pathway, and cisplatin resistance were restored by functional complementation with FANCF, a gene that is upstream in this pathway. FANCF inactivation in ovarian tumors resulted from methylation of its CpG island, and acquired cisplatin resistance correlated with demethylation of FANCF. We propose a model for ovarian tumor progression in which the initial methylation of FANCF is followed by FANCF demethylation and ultimately results in cisplatin resistance.",

author = "T Taniguchi and M Tischkowitz and N Ameziane and Hodgson, {S V} and Mathew, {C G} and H Joenje and Mok, {S C} and D'Andrea, {A D}",

year = "2003",

month = may,

day = "1",

doi = "10.1038/nm852",

language = "English",

volume = "9",

pages = "568 -- 574",

journal = "Nature Medicine",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

AU - Taniguchi, T

AU - Tischkowitz, M

AU - Ameziane, N

AU - Hodgson, S V

AU - Mathew, C G

AU - Joenje, H

AU - Mok, S C

AU - D'Andrea, A D

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Ovarian tumor cells are often genomically unstable and hypersensitive to cisplatin. To understand the molecular basis for this phenotype, we examined the integrity of the Fanconi anemia-BRCA (FANC-BRCA) pathway in those cells. This pathway regulates cisplatin sensitivity and is governed by the coordinate activity of six genes associated with Fanconi anemia (FANCA, FANCC, FANCD2, FANCE, FANCF and FANCG) as well as BRCA1 and BRCA2 (FANCD1). Here we show that the FANC-BRCA pathway is disrupted in a subset of ovarian tumor lines. Mono-ubiquitination of FANCD2, a measure of the function of this pathway, and cisplatin resistance were restored by functional complementation with FANCF, a gene that is upstream in this pathway. FANCF inactivation in ovarian tumors resulted from methylation of its CpG island, and acquired cisplatin resistance correlated with demethylation of FANCF. We propose a model for ovarian tumor progression in which the initial methylation of FANCF is followed by FANCF demethylation and ultimately results in cisplatin resistance.

AB - Ovarian tumor cells are often genomically unstable and hypersensitive to cisplatin. To understand the molecular basis for this phenotype, we examined the integrity of the Fanconi anemia-BRCA (FANC-BRCA) pathway in those cells. This pathway regulates cisplatin sensitivity and is governed by the coordinate activity of six genes associated with Fanconi anemia (FANCA, FANCC, FANCD2, FANCE, FANCF and FANCG) as well as BRCA1 and BRCA2 (FANCD1). Here we show that the FANC-BRCA pathway is disrupted in a subset of ovarian tumor lines. Mono-ubiquitination of FANCD2, a measure of the function of this pathway, and cisplatin resistance were restored by functional complementation with FANCF, a gene that is upstream in this pathway. FANCF inactivation in ovarian tumors resulted from methylation of its CpG island, and acquired cisplatin resistance correlated with demethylation of FANCF. We propose a model for ovarian tumor progression in which the initial methylation of FANCF is followed by FANCF demethylation and ultimately results in cisplatin resistance.

UR - http://www.scopus.com/inward/record.url?scp=0038075462&partnerID=8YFLogxK

U2 - 10.1038/nm852

DO - 10.1038/nm852

M3 - Article

VL - 9

SP - 568

EP - 574

JO - Nature Medicine

JF - Nature Medicine

IS - 5

ER -

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

Abstract

Access to Document

Other files and links

Fingerprint

Cite this